JACC Identifies DEFER with 5-year Outcomes as Land... (adjunct to DEFER authors have designed a...)

JACC Identifies DEFER with 5-year Outcomes as Landmark Trial

Date:3/7/2008

adjunct to DEFER, authors have designed a new 1000 patient study, Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) (American Heart Journal Volume 154, Number 4). The objective of this groundbreaking, multicenter, randomized clinical trial is to compare angiographic guidance versus fractional flow reserve (FFR) to determine which coronary lesions to stent in patients with multivessel coronary disease.

The primary end point of the study is a composite of major adverse cardiac events, including death, myocardial infarction, and repeat coronary revascularization, at 1 year.

About Radi Medical Systems AB

Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 350 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit http://www.radi.se.

Media Contacts:

David Schull or Ian Stone

Russo Partners LLC

+1 212-845-4271

david.schull@russopartnersllc.com

ian.stone@russopartnersllc.com

Jim Archetto

Radi Medical Systems Inc.

+1 877-337-7234 x812

jim.archetto@radi.se

0

GOOD

Page: 1 2
Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
3. Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood
4. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
5. St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory
6. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions

Post Your Comments:

JACC Identifies DEFER with 5-year Outcomes as Land...(adjunct to DEFER authors have designed a...),Health